Please login to the form below

Not currently logged in
Email:
Password:

XLH

This page shows the latest XLH news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn on Crystiva for rare bone disease

NICE U-turn on Crystiva for rare bone disease

NICE U-turn on Crystiva for rare bone disease. Set to back the drug to treat young people with XLH. ... This marks a step change in treatment for XLH, emphasised through the emotional testimonies provided by patient groups and clinicians following the

Latest news

  • NICE set to reject Kyowa Kirin’s Crysvita for XLH NICE set to reject Kyowa Kirin’s Crysvita for XLH

    NICE set to reject Kyowa Kirin’ s Crysvita for XLH. Committee says the rare disease therapy isn’t value for money. ... there is no treatment which targets the underlying pathophysiology of XLH – until now.

  • Rigel and Ultragenyx claim approvals for rare drugs Rigel and Ultragenyx claim approvals for rare drugs

    Rigel and Ultragenyx claim approvals for rare drugs. Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... Ultragenyx’s FDA approval was for Crysvita (burosumab), which has become the first approved drug for

  • Archive listing

    Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. .

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics